cobatrice
logo CTAD
Wednesday, November 3rd
Thursday, November 4th
Friday, November 5th
Key topics

Wednesday, November 3rd

Download the program dowload program
PRE-CTAD CONGRESS

9.00 a.m - 5.00 p.m

   LEON THAL SYMPOSIUM                          | EADC SYMPOSIUM (Members only)
8.30 a.m - 4.00 p.m   ALZHEIMER DRUG DISCOVERY FORUM


The Alzheimer’s Drug Discovery Foundation presents
Feeding the Pipeline: Novel Drug Discovery for Alzheimer’s disease
The purpose of this conference is to present exciting drug discovery efforts in the field of Alzheimer’s disease that complement approaches in advanced clinical trials. Speakers will be predominately from the European biotechnology sector. There will be ample opportunity for discussion and for scientists from academia, industry and funding organizations to network and exchange ideas



8.30 - 8.40 a.m

 

8.40 - 9.20 a.m

 

9.20 - 10.20 a.m

 

10.20 - 10.35 a.m

 

10.35 - 12.05 p.m

 

12.05 - 1.30 p.m

 

1.30 - 2.30 p.m

 

2.30 - 2.50 p.m

 

2.50 - 3.00 p.m

 

3.00 - 4.00 p.m

 





Introduction and Opening Remarks : Howard Fillit, MD, ADDF, USA

 

Plenary Session

 

Selected presentations from abstract submissions

 

Break

 

Selected presentations from abstract submissions

 

LUNCH – off site

 

Selected presentations from abstract submissions

 

Novel Funding Models for Drug Discovery : Andrea W. Tobias, Aquila Consulting Group, USA

 

Break

 

PANEL : Funding Climate for Biotechnology Companies

 

Chair : Andrea W. Tobias, Ph.D. Aquila Consulting Group
Venture Capital : Philippe Peltier, Auriga Partners (invited)
Government : Florence Lustman, Inspector General of Finances for France & Director of the French Alzheimer’s Plan (invited)
Foundation : Howard Fillit, MD, Alzheimer’s Drug Discovery Foundation

 

4.00 - 4.05 p.m

 

Closing Remarks : Howard Fillit, ADDF

 

CTAD CONGRESS

5.00 - 5.15 p.m

 

WELCOME AND INTRODUCTION
Paul Aisen, Zaven Kachaturian, Jacques Touchon, Bruno Vellas

OPENING LECTURE

5.15 - 6.00 p.m

 

Designing primary prevention trial using biomarkers
M.Weiner, University of California San Francisco, USA



CONCOMITTANT PANEL DISCUSSIONS

6.00 - 7.00 p.m

 

LEON THAL PANEL DISCUSSION
Z.Kachaturian, President & Chair
PAD2020: The Campaign to Prevent Alzheimer’s
Disease by 2020, Washington, DC, USA

REDEFINING ALZHEIMER’S DISEASE:
Revising the NINCDS-ADRDA Criteria
Chaired by M. Carillo, Alzheimer Association, USA
and P. Snyder, Lifespan Affiliated Hospitals, USA

  • Criteria for Alzheimer’s Disease Dementia
    D.Knopman, Mayo Clinic, USA
  • Criteria for Symptomatic Pre-Dementia Alzheimer’s Disease
    R.Petersen, Mayo Clinic, USA
  • Criteria for Preclinical Alzheimer’s Disease Dementia
    R.Sperling, Harvard Medical School, USA

Legal information | Tools | site MAP | | Copyright CYIM

ANT Congrès - 154 avenue de Lodève - 34070 Montpellier - France

E-mail : ctad@ant-congres.com
Tel : + 33 (0) 6 85 54 70 98
Fax : + 33 (0)4 67 10 92 23